BOTHELL, Wash., April 28 /PRNewswire-FirstCall/ -- Helix BioMedix
(OTC Bulletin Board: HXBM), a developer of synthetic bioactive peptides, today
announced that it is extending the expiration date of its tender offer to
exchange warrants that was described in its press release on March 1, 2005.
The expiration date will be extended to 9:00 a.m., New York time, on May 31,
2005, unless further extended, terminated or withdrawn. Existing warrant
shares must be tendered prior to the expiration of the exchange offer, and
tenders of existing warrant shares may be withdrawn at anytime on or prior to
the expiration of the exchange offer. Withdrawn warrant shares will be
returned to the holder in accordance with the terms of the exchange offer.
Following the expiration of the exchange offer and subject to the terms of the
exchange offer, Helix BioMedix will accept all existing warrant shares validly
tendered and not withdrawn prior to the expiration of the exchange offer and
will issue for exchange unregistered shares of common stock promptly
thereafter.
U.S. Stock Transfer Corporation is acting as the exchange agent for the
exchange offer. Questions, requests for assistance and requests for copies of
the offering circular may be obtained from Cameron Associates, which is
serving as the information agent for the exchange offer.
Neither Helix BioMedix's board of directors nor any other person makes any
recommendation as to whether holders of existing warrants should choose to
tender and exchange their existing warrant shares for shares of common stock,
and no one has been authorized to make such a recommendation. Holders of
existing warrants must make their own decisions as to whether to tender their
existing warrant shares for exchange, and, if so, how many warrant shares to
tender.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any security and shall not constitute an
offer, solicitation or sale in any jurisdiction in which such offer,
solicitation or sale would be unlawful.
About Helix BioMedix
Helix BioMedix, Inc. is an early-stage biotechnology company that has a
portfolio of issued patents that covers six distinct classes of peptides,
covering over 100,000 unique peptide sequences. The company's mission is to
become the industry leader in developing and commercializing small proteins
known as bioactive peptides. The antimicrobial and wound healing properties of
these peptides qualify them for inclusion in a wide range of both
pharmaceutical and consumer products. The company is currently focused on the
development of selected peptides as topical anti-infectives and in wound
healing. Non-pharmaceutical applications being pursued by Helix BioMedix
include adjuvants for cosmetics/cosmeceuticals, personal care, plant health,
animal health and wide-spectrum biocides. More information about the company
and its proprietary peptides can be found on the company's website at
http://www.helixbiomedix.com.
Contact:
Helix BioMedix, Inc.
David Kirske, 425-402-8400
dkirske@helixbiomedix.com
or
Investor Relations:
Cameron Associates
Alison Ziegler, 212-554-5469
alison@cameronassoc.com
SOURCE Helix BioMedix, Inc.
 back to top
Related links:
http://www.helixbiomedix.com
CONTACT:
David Kirske of Helix BioMedix, Inc.,
+1-425-402-8400, or dkirske@helixbiomedix.com, or investors,
Alison Ziegler of Cameron Associates, +1-212-554-5469, or
alison@cameronassoc.com, for Helix BioMedix, Inc.
|
